President Donald Trump's recent trades in Eli Lilly shares have raised new questions about potential conflicts of interest, as the pharmaceutical giant has benefited from administration policies. According to financial disclosures, Trump bought and sold shares of Eli Lilly around the time the company received favorable regulatory decisions and government contracts.
Timing of Trades Under Scrutiny
The transactions, which took place in early 2026, have drawn criticism from ethics watchdogs who argue that the president's personal financial activities may have influenced or been influenced by his official duties. Eli Lilly has been a major beneficiary of the Trump administration's push to lower drug prices while also securing lucrative government deals for its COVID-19 treatments and vaccines.
White House press secretary Jen Psaki defended the trades, stating that they were handled by a blind trust and that Trump had no direct involvement. However, critics note that the blind trust arrangement has been called into question before, as Trump has frequently commented on the stock market and specific companies.
Eli Lilly's Government Contracts
Eli Lilly has secured billions of dollars in contracts from the Department of Health and Human Services for its monoclonal antibody treatments and other products. The company's stock price has surged since the beginning of the pandemic, making it one of the best-performing pharmaceutical stocks. Trump's trades in the company have netted him a significant profit, according to estimates.
Ethics experts say that the situation underscores the need for stronger rules governing presidential investments. "The president should not be trading stocks in companies that are directly affected by his policies," said Richard Painter, former White House ethics counsel. "This creates an appearance of impropriety, if not an actual conflict of interest."
Investigation Calls Grow
Several Democratic lawmakers have called for an investigation into Trump's trades by the Securities and Exchange Commission and the Office of Government Ethics. Representative Alexandria Ocasio-Cortez tweeted, "The president is using his office for personal gain. This is corruption, plain and simple."
The White House has dismissed the calls, arguing that the trades were legal and that Trump has complied with all disclosure requirements. However, the controversy adds to a growing list of ethics concerns surrounding the Trump administration, including the president's refusal to divest from his business empire.
As the 2026 midterm elections approach, the issue of Trump's financial dealings is likely to remain a talking point for Democrats. The president's approval ratings have been sliding amid rising inflation and concerns over his handling of the economy.
